Influenza treatment and prophylaxis from World
Description: Influenza treatment and prophylaxis from World Health Organization Clinical practice guidelines for influenza (2024) Exposure to any influenza virus in the previous 48 hours? Exposure to a seasonal influenza virus? No antiviral No antiviral
Related Topics
Download Presentation
"Influenza treatment and prophylaxis from World" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. Influenza
treatment and prophylaxis
from World Health Organization
Clinical practice guidelines for influenza (2024) Exposure to any
influenza virus
in the previous 48 hours? Exposure to a seasonal influenza virus? No antiviral No antiviral No antiviral Was the exposure to a zoonotic influenza virus associated with high mortality in humans or unknown risk of severe disease? No antiviral For full guidance, including dosage in children and use in vulnerable populations, refer to the full guideline:
scan QR code or https://app.magicapp.org/#/guideline/jlPRdj * Baloxavir may increase the risk of antiviral resistance emerging; use with caution in immunocompromised patients.
Baloxavir is not recommended for use in pregnancy and postpartum period due to lack of safety and efficacy data.<br>
treatment and prophylaxis
from World Health Organization
Clinical practice guidelines for influenza (2024) Exposure to any
influenza virus
in the previous 48 hours? Exposure to a seasonal influenza virus? No antiviral No antiviral No antiviral Was the exposure to a zoonotic influenza virus associated with high mortality in humans or unknown risk of severe disease? No antiviral For full guidance, including dosage in children and use in vulnerable populations, refer to the full guideline:
scan QR code or https://app.magicapp.org/#/guideline/jlPRdj * Baloxavir may increase the risk of antiviral resistance emerging; use with caution in immunocompromised patients.
Baloxavir is not recommended for use in pregnancy and postpartum period due to lack of safety and efficacy data.<br>